Zhang et al in an in vitro study of the imatinib-resistant chronic myeloid leukemia cell line K562 (K562RIMT) demonstrated the inhibitory effect of dasatinib on the Pi3k/Akt/mTor signaling pathway and observed a slight upregulation of Pten at high doses of the drug [50]. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.